<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
Quarterly Report Under Section 13 or 15(d)
of the Securities Exchange Act of 1934
(Mark One)
[X] Quarterly Report Pursuant to Section 13 or 15(d) of The Securities
Exchange Act of 1934.
For the quarterly period ended December 31, 1995
---------------------------------
OR
[ ] Transition Report Pursuant to Section 13 or 15(d) of The Securities
Exchange Act of 1934.
For the transition period from to
---------------- ---------------
Commission File #0-14732
ADVANCED MAGNETICS, INC.
(Exact name of registrant as specified in its charter)
Delaware 04-2742593
(State or other jurisdiction (IRS Employer Incorporation or
of organization) Identification No.)
725 Concord Avenue
Cambridge, MA 02138
(Address of principal executive offices)
Registrant's telephone number, including area code: (617) 354-3929
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes X No
------ ------
At February 7, 1996, 6,765,332 shares of registrant's common stock (par value,
$.01) were outstanding.
Page 1 of 14
<PAGE> 2
ADVANCED MAGNETICS, INC.
FORM 10-Q
QUARTER ENDED DECEMBER 31, 1995
PART I. FINANCIAL INFORMATION
Item 1 -- Financial Statements
Page 2 of 14
<PAGE> 3
<TABLE>
ADVANCED MAGNETICS, INC.
BALANCE SHEET
DECEMBER 31, 1995 AND SEPTEMBER 30, 1995
(Unaudited)
---------
<CAPTION>
December 31, September 30,
ASSETS ------------ -------------
- ------ 1995 1995
---- ----
<S> <C> <C>
Current assets:
Cash and cash equivalents............................. $ 2,525,965 $ 1,066,419
Marketable securities (Note B)........................ 37,690,764 36,561,263
Accounts receivable................................... 1,253,735 5,884,542
Recoverable income taxes.............................. 90,117 90,117
Inventories........................................... 81,368 55,567
Prepaid expenses...................................... 68,994 99,342
----------- -----------
Total current assets................................ 41,710,943 43,757,250
----------- -----------
Property, plant and equipment:
Land.................................................. 360,000 360,000
Buildings............................................. 4,320,766 4,320,766
Laboratory equipment.................................. 7,061,149 6,886,813
Furniture and fixtures................................ 523,653 516,418
----------- -----------
12,265,568 12,083,997
Less--accumulated depreciation and amortization....... 5,406,700 5,143,097
----------- -----------
Net property, plant and equipment..................... 6,858,868 6,940,900
----------- -----------
Other assets.......................................... 145,072 145,072
----------- -----------
Total assets........................................ $48,714,883 $50,843,222
=========== ===========
LIABILITIES AND STOCKHOLDERS' EQUITY
- ------------------------------------
Current liabilities:
Accounts payable...................................... $ 556,865 $ 407,998
Accrued expenses...................................... 637,923 1,214,152
Income taxes payable.................................. 130,000 150,000
----------- -----------
Total current liabilities........................... 1,324,788 1,772,150
----------- -----------
Stockholders' equity:
Preferred stock, par value $.01 per share, authorized
2,000,000 shares; none issued........................ --- ---
Common stock, par value $.01 per share,
authorized 15,000,000 shares; issued and
outstanding 6,762,226 shares at December 31, 1995
and 6,753,413 shares at September 30, 1995........... 67,622 67,534
Additional paid-in capital............................. 45,164,561 45,093,972
Retained earnings...................................... 1,111,832 3,036,517
Unrealized gains on marketable securities (Note B)..... 1,046,080 873,049
----------- -----------
Total stockholders' equity........................... 47,390,095 49,071,072
----------- -----------
Total liabilities and stockholders' equity............. $48,714,883 $50,843,222
=========== ===========
</TABLE>
The accompanying notes are an integral part of the financial statements.
Page 3 of 14
<PAGE> 4
<TABLE>
ADVANCED MAGNETICS, INC.
STATEMENT OF OPERATIONS FOR THE QUARTERS ENDED
DECEMBER 31, 1995 AND 1994
(Unaudited)
---------
First Quarter Ended December 31,
--------------------------------
1995 1994
---- ----
<S> <C> <C>
Revenues:
Royalties............................................... $ 75,000 $ ---
Product sales........................................... --- 55,259
Interest, dividends and net gains and losses on sales of
securities............................................ 451,859 681,986
----------- ----------
Total revenues...................................... 526,859 737,245
----------- ----------
Cost and expenses:
Cost of product sold.................................... --- 11,050
Research and development expenses....................... 2,160,560 1,597,847
Credit for purchase of in-process research and
development........................................... --- (380,000)
Selling, general and administrative expenses.............. 290,984 315,890
----------- ----------
Total costs and expenses................................ 2,451,544 1,544,787
----------- ----------
(Loss) before provision for income taxes and cumulative
effect of accounting change............................. (1,924,685) (807,542)
Provision for income taxes................................ --- ---
----------- ----------
(Loss) before cumulative effect of accounting change...... (1,924,685) (807,542)
----------- ----------
Cumulative effect of accounting change.................... --- 117,540
----------- ----------
Net (loss)................................................ $(1,924,685) $ (690,002)
============ ==========
Net (loss) per share before cumulative effect of
accounting change....................................... $ (0.28) $ (0.12)
Cumulative effect of accounting change.................... --- 0.02
----------- ----------
(Loss) per share.......................................... $ (0.28) $ (0.10)
============ ==========
Weighted average number of common and common
equivalent shares....................................... 6,756,072 6,717,520
============ ==========
</TABLE>
The accompanying notes are an integral part of the financial statements.
Page 4 of 14
<PAGE> 5
<TABLE>
ADVANCED MAGNETICS, INC.
STATEMENT OF OPERATIONS FOR THE QUARTERS ENDED
DECEMBER 31, 1995 AND 1994
(Unaudited)
---------
<CAPTION>
First Quarter Ended December 31,
--------------------------------
1995 1994
---- ----
Cash flows from operating activities:
<S> <C> <C>
Cash received from customers................ $ 1,270,438 $ 54,546
Cash paid to suppliers and employees........ (2,079,507) (1,436,854)
Dividends and interest received............. 413,838 182,077
Net realized (losses) on sales of marketable
securities................................ (14,701) ---
Income taxes paid........................... (20,000) ---
----------- -----------
Net cash (used in) operating activities (429,932) (1,200,231)
----------- -----------
Cash flows from investing activities:
Purchase of securities...................... (1,450,162) (452,003)
Capital expenditures........................ (181,571) (495,300)
Proceeds from sale of marketable securities. 2,450,534 ---
Proceeds from notes and bonds maturing...... 1,000,000 ---
----------- -----------
Net cash provided by (used in) investing
activities................................ 1,818,801 (947,303)
----------- -----------
Cash flows from financing activities:
Proceeds from issuances of common stock..... 70,677 70,054
----------- -----------
Net cash provided by financing activities... 70,677 70,054
----------- -----------
Net increase (decrease) in cash and cash
equivalents............................... 1,459,546 (2,077,480)
Cash and cash equivalents at beginning of the
quarter................................... 1,066,419 6,462,193
----------- -----------
Cash and cash equivalents at end of the
quarter................................... $ 2,525,965 $ 4,384,713
=========== ===========
The accompanying notes are an integral part of the financial statements.
</TABLE>
Page 5 of 14
<PAGE> 6
<TABLE>
ADVANCED MAGNETICS, INC.
RECONCILIATIONS OF NET INCOME
TO NET CASH PROVIDED BY OPERATING ACTIVITIES
FOR THE QUARTERS ENDED DECEMBER 31, 1995 AND 1994
(Unaudited)
-----------
<CAPTION>
First Quarter Ended December 31,
--------------------------------
1995 1994
---- ----
<S> <C> <C>
Net income (loss)............................... $(1,924,685) $ (690,002)
----------- -----------
Adjustments to reconcile net income to net cash
(used in) operating activities:
Cumulative effect of accounting change....... --- (117,540)
Credit for purchase of in-process research and
development................................ --- (380,000)
Depreciation and amortization................ 263,603 232,666
(Increase) decrease in accounts receivable... 1,150,328 (500,622)
(Increase) decrease in prepaid expenses...... 30,348 (13,204)
Increase in accounts payable and accrued
expenses................................... 103,887 268,471
(Decrease) in income taxes payable........... (20,000) ---
Increase in inventories...................... (25,801) ---
Accretion of U. S. Treasury Notes discount... (7,612) ---
---------- -----------
Total adjustments.......................... 1,494,753 (510,229)
---------- -----------
Net cash (used in) operating activities......... $ (429,932) $(1,200,231)
========== ===========
</TABLE>
The accompanying notes are an integral part of the financial statements.
Page 6 of 14
<PAGE> 7
ADVANCED MAGNETICS, INC.
NOTES TO FINANCIAL STATEMENTS
DECEMBER 31, 1995
A. SUMMARY OF ACCOUNTING POLICIES.
Business
Founded in November 1981, Advanced Magnetics, Inc., a Delaware
Corporation (the "Company"), is a biopharmaceutical company engaged in the
development and manufacture of compounds utilizing the Company's core
proprietary colloidal superparamagnetic particle technology and core
polysaccharide technology for magnetic resonance imaging ("MRI") and for
polysaccharide directed, receptor-mediated drug delivery systems. The initial
products developed by the Company are diagnostic imaging agents for use in
conjunction with MRI to aid in the diagnosis of cancer and other diseases. In
therapeutics, the Company is developing antiviral products for the treatment of
hepatitis B.
The balance sheet of the Company as of December 31, 1995 and the
statement of operations and cash flows for the quarter then ended are unaudited
and in the opinion of management, all adjustments necessary for a fair
presentation of such financial statements have been recorded. Such adjustments
consisted only of normal recurring items.
Certain information and footnote disclosures normally included in
financial statements prepared in accordance with generally accepted accounting
principles have been condensed or omitted. The preparation of financial
statements in conformity with generally accepted accounting principles requires
management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at
the date of the financial statements and the reported amounts of revenues and
expenses during the reporting period. Actual results could differ from those
estimates. The year-end balance sheet data was derived from audited financial
statements, but does not include disclosures required by generally accepted
accounting principles. It is suggested that these interim financial statements
be read in conjunction with the Company's most recent Form 10-K and Annual
Report as of September 30, 1995.
B. MARKETABLE SECURITIES.
<TABLE>
The cost and market value of the Company's marketable securities
portfolio are as follows:
<CAPTION>
December 31, 1995 September 30, 1995
------------------------ ----------------------
Cost Fair Value Cost Fair Value
---- ---------- ---- ----------
<S> <C> <C> <C> <C>
U.S. government securities
Due in one year or less $ 8,500,336 $ 8,495,140 $ 9,501,365 $ 9,476,430
Due after one through five years 14,878,048 14,976,600 14,869,406 14,737,500
Corporate debt
Due after five through ten years 1,980,040 1,983,250 1,980,040 2,002,500
Preferred stock 6,612,052 6,571,046 6,116,668 5,740,023
Common Stock 4,674,208 5,664,728 3,220,735 4,604,810
----------- ----------- ----------- -----------
$36,644,684 $37,690,764 $35,688,214 $36,561,263
=========== =========== =========== ===========
</TABLE>
Common stock investment represents 55% invested in the common stock of
one company.
Page 7 of 14
<PAGE> 8
C. INCOME TAX
There was no income tax provision for the first fiscal quarters ended
December 31, 1995 and 1994 due to an operating loss in each quarter.
D. LEGAL PROCEEDINGS
The Company and certain of its officers were sued in an action in the
United States District Court for the District of Massachusetts on September 3,
1992. The plaintiff, a former consultant to the Company, claims that he was
incorrectly omitted as an inventor or joint inventor on certain of the
Company's patents and on pending applications, and seeks injunctive relief and
unspecified monetary damages. The plaintiff filed a related case in the
Superior Court of the Commonwealth of Massachusetts. The Superior Court has
dismissed most of the claims on summary judgment. While the final outcome of
these actions cannot be determined, the Company believes that the plaintiff's
claims are without merit and intends to defend the actions vigorously.
Page 8 of 14
<PAGE> 9
ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS.
OVERVIEW
Since its inception in November 1981, Advanced Magnetics, Inc., ("the
Company") has focused its efforts on developing its core magnetic particle
technology for in-vitro and in-vivo diagnostics. In recent years, efforts have
focused on the development of magnetic resonance imaging (MRI) contrast agents
as well as the Company's core polysaccharide technology for the delivery of
antiviral therapeutics. The Company has funded its operations with cash from
license fees, royalties, sales of its products, fees from contract research
performed for third parties, the proceeds of financings and income earned on
invested cash. The Company's ultimate success in the marketing of diagnostic
and therapeutic products will depend, in part, on the Company's ability to
successfully develop, test, produce and market its products; obtain the
necessary governmental approvals in a timely manner; attract and maintain key
employees; and successfully respond to technological changes in its
marketplaces.
The Company's operating results may continue to vary significantly from
quarter to quarter or from year to year depending on a number of factors,
including: the timing of payments from corporate partners and research grants;
the introduction of new products by the Company; the timing and size of orders
from the Company's customers; and the general level of acceptance of the
Company's products. The Company's current planned expense levels are based in
part upon expectations as to future revenue. Consequently, profits may vary
significantly from quarter to quarter or year to year based on the timing of
revenue. Revenue or profits in any period will not necessarily be indicative of
results in subsequent periods and there can be no assurance that the Company
will achieve profitability or that revenue growth will occur in the future.
A substantial portion of the Company's expenses consists of research and
development expenses. The Company expects its research and development expenses
to increase as it funds additional clinical trials and associated toxicology and
pharmacology studies and as it devotes resources to developing additional
contrast agents and new therapeutic drugs.
The discussion in this Item 2 contains some forward looking statements
which involve certain risks and uncertainties, including statements related to
expenditures on research and development, liquidity and capital resources and
capital expenditures.
RESULTS OF OPERATIONS FOR THE QUARTER ENDED DECEMBER 31, 1995 AS COMPARED TO
- ----------------------------------------------------------------------------
THE QUARTER ENDED DECEMBER 31, 1994.
- ------------------------------------
REVENUES
Total revenues for the first fiscal quarter ended December 31, 1995
decreased 29% to $526,859 from $737,245 for the first fiscal quarter ended
December 31, 1994. The Company's revenues historically consist primarily of
license fees, royalties on product sold by licensees, direct sales of products
and investment income. The decrease in revenues compared to the first fiscal
quarter ended December 31, 1994 resulted primarily from the absence of product
sales and a reduction in interest and dividend income earned on investments and
was partially offset by an increase in revenue from royalties.
Royalties for the first fiscal quarter ended December 31, 1995 were
$75,000 and were paid by Guerbet S.A. on European product sales of the Company's
Feridex I.V.[TM] and GastroMARK[R] MRI contrast agents. There were no royalties
for the first fiscal quarter ended December 31, 1994.
There were no products shipped during the first fiscal quarter ended
December 31, 1995 compared to $55,259 shipped in the comparable prior fiscal
year period.
Page 9 of 14
<PAGE> 10
<TABLE>
Interest, dividends and gains and losses on sales of securities resulted
in revenues of $451,859 for the first fiscal quarter ended December 31, 1995
compared to $681,986 for the first fiscal quarter ended December 31, 1994.
Interest, dividends and net gains (losses) on sales of securities consist of the
following:
<CAPTION>
First Fiscal Quarter Ended December 31,
---------------------------------------
1995 1994
---------------------------------------
<S> <C> <C>
Interest income $345,687 $425,850
Dividend income 120,873 256,136
Net gains on sales of securities (14,701) -0-
-------- --------
$451,859 $681,986
======== ========
</TABLE>
Interest income for the first fiscal quarter ended December 31, 1995 was
$80,163 less than the first fiscal quarter ended December 31, 1994 primarily due
to a reduction of funds invested in money market accounts.
Dividend income for the first fiscal quarter ended December 31, 1995 was
$135,263 less than the first fiscal quarter ended December 31, 1994 primarily
due to a reduction of funds invested in dividend paying preferred stocks. There
were no sales of securities in the first fiscal quarter ended December 31, 1994.
COSTS AND EXPENSES
Research and development expenses for the first fiscal quarter ended
December 31, 1995 increased 35% to $2,160,560 from $1,597,847 for the first
fiscal quarter ended December 31, 1994. The increase is primarily a result of
costs associated with Phase III human clinical trials for the Company's
Combidex[TM] contrast agent for use in imaging lymph nodes, liver, spleen and
blood vessels. The first fiscal quarter ended December 31, 1994 reflected a
$380,000 credit for the reversal of the purchase of in-process research and
development expenses that were expensed in the fiscal year ended September 30,
1994 as part of the Company's Combidex transaction with Squibb Diagnostics, a
division of Bristol-Myers Squibb Co. Selling, general and administrative
expenses decreased 8% to $290,984 for the first fiscal quarter ended December
31, 1995 from $315,890 for the first fiscal quarter ended December 31, 1994.
The decrease is primarily due to a decrease in legal and consulting fees.
The Company incurred no costs of product sold for the first fiscal
quarter ended December 31, 1995 compared to $11,050 for the first fiscal quarter
ended December 31, 1994.
OTHER
The Company adopted Statement of Financial Standards No. 115,
"Accounting for Certain Investments in Debt and Equity Securities," in the first
fiscal quarter ended December 31, 1994. As a result, the Company recorded a
cumulative effect for the accounting change of $117,540. There was a loss
before the cumulative effect for the accounting change of $807,542 for the first
fiscal quarter ended December 31, 1994.
INCOME TAXES
There was no income tax provision for the first fiscal quarters ended
December 31, 1995 and 1994 due to an operating loss in each quarter.
EARNINGS
For the reasons stated above, there was a net loss of $1,924,685 or
$0.28 per share for the first fiscal quarter ended December 31, 1995 compared to
a net loss of $690,002 or $0.10 per share for the first fiscal quarter ended
December 31, 1994.
Page 10 of 14
<PAGE> 11
LIQUIDITY AND CAPITAL RESOURCES
At December 31, 1995, the Company's cash and cash equivalents totaled
$2,525,965, representing an increase of $1,459,546 from cash and cash
equivalents at September 30, 1995. In addition, the Company had marketable
securities of $37,690,764 at December 31, 1995. Net cash used in operating
activities was $429,932 in the first fiscal quarter ended December 31, 1995
compared to net cash used in operating activities of $1,200,231 in the first
fiscal quarter ended December 31, 1994. Cash used in operating activities for
the first fiscal quarter ended December 31, 1995 was less than the cash used in
operating activities for the first fiscal quarter ended December 31, 1994 due
primarily to the collection of accounts receivable of $1,150,328, offset by an
increase in the net loss for the quarter. Cash provided by investing activities
was $1,818,801 for the first fiscal quarter ended December 31, 1995 compared to
$947,303 used in investing activities in the first fiscal quarter ended December
31, 1994. Cash provided by investing activities in the first fiscal quarter
ended December 31, 1995 included the proceeds of $2,450,534 from the sale of
marketable securities and proceeds from a $1,000,000 matured United States
Treasury Note. Offsetting these proceeds was the purchase of marketable
securities of $1,450,162 in the first fiscal quarter ended December 31, 1995.
Cash provided by financing activities for the first fiscal quarter ended
December 31, 1995 and 1994 was $70,677 and $70,054 respectively, which resulted
from the issuance of common stock.
Capital expenditures in the first fiscal quarter ended December 31, 1995
were $181,571 compared to $495,300 in the first fiscal quarter ended December
31, 1994. Capital expenditures in the first fiscal quarter ended December 31,
1994 included an upgrade to the Company's magnetic resonance imaging equipment
and furnishings and equipment associated with the establishment of the Clinical
Development Group in the Company's Princeton, New Jersey office. The Company
has no current commitment for any significant expenditures on property, plant
and equipment. The Company expects that expenditures for research and
development for the remainder of fiscal 1996 will continue to increase due to
human clinical trials for the Company's development stage contrast agents and
antiviral hepatitis therapeutics.
On October 15, 1993, the Company sold its in-vitro product line to
PerSeptive Biosystems, Inc. ("PerSeptive") for $4,156,674 in PerSeptive's common
stock, plus an earn-out based on PerSeptive`s fiscal 1995 in-vitro product line
revenues. The Company recognized a pre-tax gain of $2,649,580 in the first
fiscal quarter of 1994. The Company was advised by PerSeptive that the earn-out
value was $3,404,527 and, accordingly, the company recognized a related pre-tax
gain and receivable of $3,404,527 in the fourth fiscal quarter of 1995. On
December 20, 1995, PerSeptive delivered as payment to the Company, 378,080
shares of PerSeptive common stock which is included in investments at December
31, 1995.
Management believes that funds for future needs can be generated from
existing cash balances, cash generated from investing activities and cash
generated from operations. In addition, the Company will consider from time to
time various financing alternatives and may seek to raise additional capital
through equity or debit financing or to enter into corporate partnering
arrangements. There can be no assurance, however, that such funding will be
available on terms acceptable to the Company, if at all.
Page 11 of 14
<PAGE> 12
PART II. OTHER INFORMATION
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
Statement regarding computation of Per Share Earnings is filed in Part
II, Exhibit 11, of this report.
Page 12 of 14
<PAGE> 13
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ADVANCED MAGNETICS, INC.
Date February 14, 1996 By /s/ Jerome Goldstein
---------------------- ------------------------------------------------
Jerome Goldstein, President,
Treasurer and Chairman of the Board of Directors
Date February 14, 1996 By /s/ Anthony P. Annese
---------------------- ------------------------------------------------
Anthony P. Annese, Vice President
and Principal Accounting Officer
<PAGE> 1
<TABLE>
ADVANCED MAGNETICS, INC.
Exhibit 11 - Statement Re Computation of Per Share Earnings
Attached to and made part of Part II of Form 10-Q for Quarter Ended
<CAPTION>
December 31,
-------------------------
1995 1994
---- ----
<S> <C> <C>
Weighted average number of shares issued and outstanding 6,756,072 6,717,520
--------- ---------
</TABLE>
As a result of a net loss in the quarters ended December 31, 1995 and 1994,
common stock equivalents are not included in the calculation of weighted
average shares when their effect would be antidulative.
Page 14 of 14
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM BALANCE
SHEET DECEMBER 31, 1995 AND SEPTEMBER 30, 1995; STATEMENT OF OPERATIONS FOR THE
QUARTERS ENDED DECEMBER 31, 1995 AND 1994; AND STATEMENT OF CASH FLOW FOR THE
QUARTERS ENDED DECEMBER 31, 1995 AND 1994, AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FORM 10-Q FOR PERIOD ENDING DECEMBER 31, 1995.
</LEGEND>
<MULTIPLIER> 1
<CURRENCY> U.S. DOLLARS
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> SEP-30-1995
<PERIOD-START> OCT-01-1995
<PERIOD-END> DEC-31-1995
<EXCHANGE-RATE> 1
<CASH> 2,525,965
<SECURITIES> 37,690,764
<RECEIVABLES> 1,253,735
<ALLOWANCES> 0
<INVENTORY> 81,368
<CURRENT-ASSETS> 41,710,943
<PP&E> 12,265,568
<DEPRECIATION> 5,406,700
<TOTAL-ASSETS> 48,714,883
<CURRENT-LIABILITIES> 1,324,788
<BONDS> 0
<COMMON> 67,622
0
0
<OTHER-SE> 0
<TOTAL-LIABILITY-AND-EQUITY> 48,714,883
<SALES> 0
<TOTAL-REVENUES> 526,859
<CGS> 0
<TOTAL-COSTS> 2,451,544
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (1,924,685)
<INCOME-TAX> (20,000)
<INCOME-CONTINUING> 0
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (1,924,685)
<EPS-PRIMARY> (0.28)
<EPS-DILUTED> (0.28)
</TABLE>
